## 3 Results  
Table 1 summarizes the clinical and laboratory characteristics of the study population. We divided patients into two groups: survivor and non-survivor patients at a long-term (6-year) follow-up. \begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Characteristics** & **All Patients** & **Survivors** & **Non-Survivors** & _p-Values_ \\ \hline Total number of patients (n, \%) & 47 (100) & 27 (100) & 20 (100) & \\ Mean age (years) & 58.6 \(\pm\) 13.1 & 55.3 \(\pm\) 11.3 & 62.9 \(\pm\) 14.4 & 0.048 \\ Hypertension (n, \%) & 21 (44.7) & 13 (48.1) & 8 (40) & 0.59 \\ Diabetes (n, \%) & 2 (4.3) & 1 (3.7) & 1 (5) & 0.83 \\ Dyslipidemia (n, \%) & 6 (12.8) & 5 (18.5) & 1 (5) & 0.18 \\ Ischemic heart disease (n, \%) & 2 (4.3) & 1 (3.7) & 1 (5) & 0.83 \\ Peripheral artery disease (n, \%) & 2 (4.3) & 0 (0) & 2 (10) & 0.10 \\ Previous stroke or TIA (n, \%) & 2 (4.3) & 0 (0) & 2 (10) & 0.10 \\ Family history CVD (n, \%) & 19 (40.4) & 13 (48.1) & 6 (30) & 0.22 \\ Smoking (n, \%) & 3 (6.4) & 1 (3.7) & 2 (10) & 0.39 \\ Chemotherapy (n, \%) & 32 (68.1) & 15 (55.5) & 17 (85) & 0.03 \\ Type of chemotherapy & & & & \\ Doxorubicin alone (n, \%) & 1 (2.1) & 0 (0) & 1 (5) & 0.25 \\ Paclitaxel alone (n, \%) & 1 (2.1) & 1 (3.7) & 0 (0) & 0.39 \\ Carboplatin + paclitaxel (n, \%) & 21 (44.7) & 13 (48.1) & 8 (40) & 0.59 \\ Carboplatin + paclitaxel + & & 9 (19.1) & 7 (25.9) & 2 (10) & 0.17 \\ bevacizumab (n, \%) & & & & \\ Surgical intervention (n, \%) & 18 (38.3) & 14 (51.8) & 4 (20) & 0.03 \\ Type of cancer & & & & \\ Ovarian cancer diagnosis (n, \%) & 25 (53.2) & 14 (51.8) & 11 (55) & \\ Endometrial cancer diagnosis (n, \%) & 13 (27.7) & 8 (29.6) & 5 (25) & \\ Uterine cervix cancer diagnosis (n, \%) & 7 (14.9) & 5(18.5) & 2 (10) & \\ Vulvar cancer diagnosis (n, \%) & 2 (4.3) & 0 (0) & 2 (10) & \\ Follow-up duration (days) & 1364.3 \(\pm\) 676.1 & 1870.5 \(\pm\) 120.1 & 680.9 \(\pm\) 480.1 & \textless{}0.0001 \\ Laboratory evaluation & & & & \\ RBC (\(\times 10^{6}/\text{mm}^{3}\)) & 4.21 \(\pm\) 0.37 & 4.25 \(\pm\) 0.32 & 4.15 \(\pm\) 0.43 & 0.39 \\ WBC (\(\times 10^{3}/\text{mm}^{3}\)) & 6.39 \(\pm\) 2.24 & 6.58 \(\pm\) 2.31 & 6.14 \(\pm\) 2.18 & 0.51 \\ Hb (g/dL) & 12.0 \(\pm\) 1.2 & 11.9 \(\pm\) 1.2 & 12.1 \(\pm\) 1.2 & 0.61 \\ HCT (\%) & 36.2 \(\pm\) 3.4 & 35.7 \(\pm\) 2.9 & 37.0 \(\pm\) 3.8 & 0.20 \\ MCH (\(\mu\)g/mL) & 28.6 \(\pm\) 2.7 & 28.0 \(\pm\) 2.6 & 29.5 \(\pm\) 2.6 & 0.06 \\ MCHC (ug/mL) & 33.2 \(\pm\) 1.5 & 33.4 \(\pm\) 1.4 & 32.9 \(\pm\) 1.6 & 0.32 \\ MCV (IL) & 86.4 \(\pm\) 6.8 & 84.0 \(\pm\) 5.9 & 89.5 \(\pm\) 6.9 & 0.006 \\ PLT (\(\times 10^{3}/\text{mm}^{3}\)) & 268.1 \(\pm\) 92.2 & 253.6 \(\pm\) 79.1 & 287.5 \(\pm\) 106.4 & 0.22 \\ Total cholesterol (mg/dL) & 179.2 \(\pm\) 28.4 & 179.1 \(\pm\) 31.4 & 179.3 \(\pm\) 24.6 & 0.98 \\ TG (mg/dL) & 109.4 \(\pm\) 28.4 & 109.6 \(\pm\) 31.1 & 109.0 \(\pm\) 26.4 & 0.94 \\ HDL-C (mg/dL) & 48.9 \(\pm\) 8.8 & 49.0 \(\pm\) 7.7 & 48.7 \(\pm\) 10.4 & 0.93 \\ LDL-C (mg/dL) & 108.5 \(\pm\) 29.1 & 108.2 \(\pm\) 30.7 & 108.8 \(\pm\) 27.6 & 0.95 \\ Fasting glycemia (mg/dL) & 96.9 \(\pm\) 27.1 & 97.5 \(\pm\) 32.3 & 96.2 \(\pm\) 18.7 & 0.88 \\ Creatinine (mg/dL) & 0.71 \(\pm\) 0.21 & 0.71 \(\pm\) 0.18 & 0.71 \(\pm\) 0.24 & 0.97 \\ \hline \hline \end{tabular} Numbers are expressed as the mean \(\pm\) standard deviation or number and percentages. Abbreviations: CVD: cardiovascular diseases; Hb: hemoglobin; HCT: hematocrit; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; MCV: mean corpuscular volume; PLT: platelets; RBC: red blood cells; TG triglycerides; TIA: transient ischemic attack; WBC: white blood cells.  
\end{table} 
Table 1: Baseline characteristics of the overall study population of surviving and non-surviving patients. Twenty patients (42%) died by the time of the 6-year follow-up. Both groups were similar according to the common cardiovascular risk factors.